A Phase 1, Multi-center, Open-label, Dose De-escalation Study to Evaluate the Safety and Efficacy of Talimogene Laherparepvec in Pediatric Subjects With Advanced Non Central Nervous System Tumors That Are Amenable to Direct Injection
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Talimogene laherparepvec (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Amgen
- 29 May 2017 Planned End Date changed from 18 Jan 2021 to 20 Dec 2021.
- 29 May 2017 Planned primary completion date changed from 5 Mar 2019 to 4 Feb 2020.
- 07 Apr 2017 Planned initiation date changed from 1 May 2017 to 28 Jul 2017.